Trial Profile
Phase I trial of COTI 2 in patients with recurrent head and neck squamous cell cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2018
Price :
$35
*
At a glance
- Drugs COTI 2 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 25 Jan 2018 According to a Cotinga Pharmaceuticals media release, the company expects to report initial safety data in the second quarter of 2018.
- 25 Jan 2018 Status changed from planning to recruiting, according to a Cotinga Pharmaceuticals media release.
- 22 Jan 2015 New trial record